{"DataElement":{"publicId":"6296255","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Combined Ann Arbor Stage","preferredDefinition":"The combined anatomic stages for diffuse large B-cell lymphoma using Ann Arbor classification criteria.","longName":"DLBCL_AA_COM_STAGE","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6296247","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Combined","preferredDefinition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma._Made or joined or united into one or involving the joint activity of two or more.","longName":"2478319v1.0:6296245v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2478319","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma","preferredDefinition":"This non-Hodgkin's lymphoma is characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin's lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, T-cell/histiocyte rich lymphoma, anaplastic lymphoma, plasmablastic lymphoma, and diffuse large B-cell lymphoma with expression of full-length ALK. (WHO, 2001) -- 2003","longName":"C8851","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma","conceptCode":"C8851","definition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"11E01CB8-267E-253F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-04-20","modifiedBy":"ONEDATA","dateModified":"2006-04-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6296245","version":"1","preferredName":"Combined","preferredDefinition":"Made or joined or united into one or involving the joint activity of two or more.","longName":"C25454","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Combined","conceptCode":"C25454","definition":"Made or joined or united into one or involving the joint activity of two or more.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C7E817B-E515-351C-E053-F662850AC7C1","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-18","modifiedBy":"ONEDATA","dateModified":"2018-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C7E817B-E526-351C-E053-F662850AC7C1","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-18","modifiedBy":"TAYLORT","dateModified":"2018-06-29","changeDescription":"6/29/18 approved/released tt. 5/18/18 tt/10126 & 10106","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6296252","version":"1","preferredName":"Combined Diffuse Large B-Cell Lymphoma Ann Arbor Stage","preferredDefinition":"An anatomic stage for diffuse large B-cell lymphoma based on the Ann Arbor classification criteria._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"6296252v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"12","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stage III/IV","valueDescription":"Ann Arbor Stage III/IV Diffuse Large B-Cell Lymphoma","ValueMeaning":{"publicId":"6296253","version":"1","preferredName":"Ann Arbor Stage III/IV Diffuse Large B-Cell Lymphoma","longName":"6296253","preferredDefinition":"Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).: Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","conceptCode":"C8856","definition":"Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","conceptCode":"C8857","definition":"Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C800E86-4130-4A1D-E053-F662850A15E9","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6C800E86-4149-4A1D-E053-F662850A15E9","beginDate":"2018-05-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-18","modifiedBy":"ONEDATA","dateModified":"2018-05-18","deletedIndicator":"No"},{"value":"Stage I/II","valueDescription":"Ann Arbor Stage I/II Diffuse Large B-Cell Lymphoma","ValueMeaning":{"publicId":"6296254","version":"1","preferredName":"Ann Arbor Stage I/II Diffuse Large B-Cell Lymphoma","longName":"6296254","preferredDefinition":"Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).: Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ann Arbor Stage I Diffuse Large B-Cell Lymphoma","conceptCode":"C8854","definition":"Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","conceptCode":"C8855","definition":"Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C800E86-4156-4A1D-E053-F662850A15E9","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6C800E86-416F-4A1D-E053-F662850A15E9","beginDate":"2018-05-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-18","modifiedBy":"ONEDATA","dateModified":"2018-05-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6296031","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma by Ann Arbor Stage Stage","preferredDefinition":"An anatomic stage for diffuse large B-cell lymphoma based on the Ann Arbor classification criteria.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C141254:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma by Ann Arbor Stage","conceptCode":"C141254","definition":"An anatomic stage for diffuse large B-cell lymphoma based on the Ann Arbor classification criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C7D1922-DA24-7805-E053-F662850A88D9","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-18","modifiedBy":"ONEDATA","dateModified":"2018-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C800E86-4115-4A1D-E053-F662850A15E9","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-18","modifiedBy":"TAYLORT","dateModified":"2018-06-29","changeDescription":"6/29/18 approved/released tt. 5/18/18 tt/10126 &10106.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"DLBL0131","type":"OID, Theradex","context":"Theradex"}],"ReferenceDocuments":[{"name":"Ann Arbor Stage","type":"Preferred Question Text","description":"Ann Arbor Stage","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C800E86-4179-4A1D-E053-F662850A15E9","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"6/29/18 approved/released tt. 5/18/18 tt/10126 &10106.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}